Llovet Fernando, Galal Ahmed, Benitez-del-Castillo Jose-Manuel, Ortega Julio, Martin Clara, Baviera Julio
Clínica Baviera/Instituto Oftalmológico Europeo, Madrid, Spain.
J Cataract Refract Surg. 2009 Jul;35(7):1156-65. doi: 10.1016/j.jcrs.2009.03.014.
To evaluate the visual and refractive results of hyperopic LASIK.
Clínica Baviera Instituto Oftalmológico Europeo, Madrid, Spain.
This retrospective consecutive noncomparative observational study evaluated hyperopic LASIK results over 1 year. Outcomes included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), cycloplegic refraction, and corneal topography. Surgery was performed using an MEL 80-G excimer laser. Results were analyzed by preoperative spherical equivalent (SE) (Group 1: <or=+3.50 diopters [D]; Group 2: >or=+3.60 D).
The mean UDVA improved from 0.50 +/- 0.3 (SD) to 0.90 +/- 0.2 in Group 1 and from 0.50 +/- 0.3 to 0.80 +/- 0.2 in Group 2 and the mean CDVA, from 0.86 +/- 0.2 to 0.93 +/- 0.1 and from 0.80 +/- 0.2 to 0.90 +/- 0.2, respectively. The mean cycloplegic SE improved from +2. 5+/- 0.8 to +0.1 +/- 0.5 in Group 1 and from +4.5 +/- 0.6 to +0.4 +/- 0.6 in Group 2; 70.9% of eyes and 63.3% of eyes, respectively, were within +/-0.50 D of emmetropia. Postoperatively, 92.8% of eyes in Group 1 and 87.8% in Group 2 maintained or gained 1 or more lines of CDVA; 1.7% and 4.0%, respectively, lost 2 or more lines. The safety index was 1.1 in both groups and the efficacy index, 1.01 in Group 1 and 0.98 in Group 2. The enhancement rate was 20.0% and 18.4%, respectively.
Excimer laser LASIK was safe and effective for treating hyperopia up to +6.25 D with no further loss of CDVA lines after enhancement.
评估远视性准分子激光原位角膜磨镶术（LASIK）的视力和屈光结果。
西班牙马德里的欧洲眼科研究所巴维埃拉诊所。
这项回顾性连续非对照观察性研究评估了1年以上的远视性LASIK结果。结果包括未矫正远视力（UDVA）、矫正远视力（CDVA）、睫状肌麻痹验光和角膜地形图。手术使用MEL 80 - G准分子激光进行。结果按术前等效球镜度（SE）分析（第1组：≤ +3.50屈光度[D]；第2组：≥ +3.60 D）。
第1组平均UDVA从0.50±0.3（标准差）提高到0.90±0.2，第2组从0.50±0.3提高到0.80±0.2；平均CDVA分别从0.86±0.2提高到0.93±0.1和从0.80±0.2提高到0.90±0.2。第1组平均睫状肌麻痹SE从 +2.5±0.8提高到 +0.1±0.5，第2组从 +4.5±0.6提高到 +0.4±0.6；分别有70.9%和63.3%的眼睛在正视眼的±0.50 D范围内。术后，第1组92.8%的眼睛和第2组87.8%的眼睛保持或提高了1行或更多行CDVA；分别有1.7%和4.0%的眼睛下降了2行或更多行。两组的安全指数均为1.1，第1组的疗效指数为1.01，第2组为0.98。增强率分别为20.0%和18.4%。
准分子激光LASIK治疗高达 +6.25 D的远视是安全有效的，增强后CDVA行数无进一步损失。
